Pet care has significantly advanced in recent years, most notably in the wearable veterinary diagnostics niche. I'm keen to explore the progress of the sector’s innovators and what this means for the market.
Recruiter conferences are rich opportunities to learn and develop, but what are the key benefits to prepare for before you attend? Let’s break it down.
In this episode of Diagnostics Digest, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS) and Chief NHS Pathologist during COVID-19. Click to listen now.
In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with Beth Cobb, Chief Operating Officer at NOWDiagnostics | NowDx.
How have animal diagnostics companies adapted to stay relevant and successful post-pandemic? We explore companies across the industry to find out.
First, it's one of Boston's 'Best Small Companies To Work For', then it announced a major Labcorp partnership. But how have Weavr Health overcome the challenges of retaining a core company culture when scaling a fast-growing start-up?
Predicine With a background in research, pharma and commercial, Dennis gives insight into the true value of liquid biopsy. Click to listen.
This is the first in a new CM Life Science series discussing trends and insights into the diagnostics market. Here I'm joined by Delphine, to discuss European market expansion strategies within the diagnostics space. Click to listen.
As the Theranos and Holmes trial finally comes to a close, what has been the effect of the CEO’s 15 years of fraudulent tenure on the diagnostics industry?
.jpg)
More and more start-ups and MNEs are taking over, each of them contributing with innovative technologies and processes, promising a better future for the industry. Click to find out more.
In this episode of CM Conversation, I spoke to Miron Tokarski, CEO of Genomtec, a company operating in the field of clinical diagnostics. Also joining us was Magdalena Kicińska, Marketing Partner at Genomtec. Click to listen to the full episode.
Bioinformatics is transforming personalised care for cancer and rare diseases and aiding in novel drug discovery. In this article, I wanted to highlight the work and progress being made by some of the top companies in the space.
I’d like to celebrate these hard-working people by acknowledging the technologies behind four of the most innovative start-ups disrupting blood-based diagnostics right now. Click to find out who they are.
POC diagnostics has played a crucial role in the fight against COVID-19. In this episode of CM Conversations, I speak to Jonathan O’Halloran, who is CEO at QuantuMDx and an industry expert. I ask him: What's next for POC diagnostics?
Toxicology is such an exciting space to be working in right now, with the market continuing innovate. Within this article, I wanted to share just some of the innovative companies that I’ve seen help take toxicology to new heights.
.jpg)
Diagnostics still has a crucial role to play in combating COVID-19 and, with new funding, a lot of exciting plans too. To find out more, I spoke to Jonathan O’Halloran, who is CEO at QuantuMDx.
What do you want from diagnostics? Before COVID-19, this wouldn’t have been a question at the forefront of so many peoples' minds. However, now it is and consumers are demanding changes to the industry.
.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
More and more companies are striving to build diverse and inclusive teams. I wanted to speak to an expert at this, who works within the life sciences arena, to find out what they do.
To gain further insight into how labs have adapted, the CM Life Science team spoke to three North American market leaders in laboratory testing services about how they’ve supported the US healthcare system.
Consistent early detection is considered the 'holy grail' of cancer diagnosis. If you can catch cancer early enough, you can stop it from developing. Liquid biopsy could be the key to unlocking that potential.
.jpg)
The diagnostics space is doing crucial work to detect and limit the spread of Covid-19 all over the world – with companies both big and small contributing to the cause
In the US alone, a report by the Centers for Disease Control and Prevention (CDC) in March this year highlighted how 2.8 million antibiotic-resistant infections occur each year, leading to the deaths of more than 35,000 people.
The approach to fighting coronavirus has not differed to the fight against any other outbreak in terms of what is required to control it.
To achieve the WHO's ambitious aim that no woman should die of cervical cancer by 2030 it will take a huge, global effort from companies around the world. Luckily, there is a global community of life sciences companies to help achieve that aim.
To find out more about Bond Health, I spoke to Phil Groom, Commercial Director, and Viktoriya Agova, Marketing Manager from Bond Health to hear how they're connecting the world of lateral flow.
.jpg)
COVID-19 is one of the biggest challenges healthcare has ever faced. Crucial work is being done throughout molecular diagnostics to limit the spread in what many would call the space's finest hour.
Creating a test that's able to identify all autoimmune diseases in one go would be the golden-ticket diagnostic solution – speeding up diagnosis across the board.
There’s so much more to the UK biotech scene than just London and Cambridge. In the North, we're surrounded by many fascinating companies who’re innovating and conducting crucial research.
It's humbling to see how the life science community has come together to combat the coronavirus. Here's what's happening in diagnostics.
